This article was originally published on PharmaTimes http://www.pharmatimes.com/news/uk_breast_cancer_patients_win_early_access_to_tecentriqnab-paclitaxel_1281599

Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) have won early access to Roche’s immunotherapy Tecentriq in combination with nab-paclitaxel chemotherapy.

Related Posts